Michele Murzi

Dr. Michele Murzi


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2015 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MGMATTIA GLAUBER
MATTIA GLAUBER
AMAntonio Miceli
Antonio Miceli
DCDaniele Canarutto
Daniele Canarutto
ALAntonio Lio
Antonio Lio
MMMichele Murzi
Michele Murzi
MSMarco Solinas
Marco Solinas
To report early and long-term outcomes of patients undergoing minimally invasive mitral valve surgery (MIMVS) through right mini-thoracotomy (RT) over a 10-year period. From September 2003 to December 2013, a total of 1604 consecutive patients underwent MIMVS through RT. The mean age was 63 ± 13 years, 770 (48 %) patients were female and 218 (13.6 %) had previous cardiac operations. The most predominant pathology was degenerative disease (70 %), followed by functional mitral valve regurgitation (12 %), rheumatic disease (9.4 %), endocarditis (5 %) and prosthetic dysfunction (3.2 %). Mitral valve repair was performed in 1137 (71 %) patients and 476 (29 %) had mitral valve replacement. Direct aortic cannulation was achieved in 1325 (83 %) patients. Among patients with degenerative disease candidate for repair (n = 958), rate of mitral valve repair was 95 %. Repair techniques included annuloplasty (95 %), leafleat resection (63 %), neochordae implantation (16 %) and sliding plasty (11 %). Concomitant procedures included tricuspid valve repair (14.6 %), atrial fibrillation ablation (9.5 %) and atrial septal defect closure (3.2 %). Overall in-hospital mortality was 1.1 %. Thirty-four patients (2.1 %) had conversion to sternotomy. Incidence of stroke was 2 %. Overall survival at 10 years was 88 ± 2 %. Freedom from reoperation at 10 years was 94 ± 2 % for repair and 80 ± 6 % for replacement. Freedom from recurrent mitral regurgitation >3+ at 10 years was 90 ± 3 %. Minimally invasive mitral valve surgery is a safe and reproducible approach associated with low mortality and morbidity, high rate of mitral valve repair and excellent late results.

1 December 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MMMichele Murzi
Michele Murzi
AMAntonio Miceli
Antonio Miceli
GSGioia Di Stefano
Gioia Di Stefano
ACAlfredo Giuseppe Cerillo
Alfredo Giuseppe Cerillo
PFPierandrea Farneti
Pierandrea Farneti
MGMattia Glauber
Mattia Glauber

1 May 2021 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Simona CeliSimona Celi
Simona Celi
EGEmanuele Gasparotti
Emanuele Gasparotti
KCKatia Capellini
Katia Capellini
EVEmanuele Vignali
Emanuele Vignali
BFBenigno Marco Fanni
Benigno Marco Fanni
Vincenzo PositanoVincenzo Positano
Vincenzo Positano
Background: 3D printing represents an emerging technology in the field of cardiovascular medicine. 3D printing can help to perform a better analysis of complex anatomies to optimize intervention planning. Methods: A systematic review was performed to illustrate the 3D printing technology and to describe the workflow to obtain 3D printed models from patient-specific images. Examples from our laboratory of the benefit of 3D printing in planning interventions were also reported. Results: 3D printing technique is reliable when applied to high-quality 3D image data (CTA, CMR, 3D echography), but it still needs the involvement of expert operators for image segmentation and mesh refinement. 3D printed models could be useful in interventional planning, although prospective studies with comprehensive and clinically meaningful endpoints are required to demonstrate the clinical utility. Conclusion: 3D printing can be used to improve anatomy understanding and surgical planning.

1 December 2016 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MMMichele Murzi
Michele Murzi
ACAlfredo Giuseppe Cerillo
Alfredo Giuseppe Cerillo
DGDanyar Gilmanov
Danyar Gilmanov
GCGiovanni Concistrè
Giovanni Concistrè
PFPierandrea Farneti
Pierandrea Farneti
MSMarco Solinas
Marco Solinas

9 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Antonio RizzaAntonio Rizza
Antonio Rizza
Giancarlo TrimarchiGiancarlo Trimarchi
Giancarlo Trimarchi
SSSilvia Di Sibio
Silvia Di Sibio
LBluca bastiani
luca bastiani
MMMichele Murzi
Michele Murzi
Sergio BertiSergio Berti
Sergio Berti
In the context of thoracic endovascular aortic repair (TEVAR), the reconstruction of the left subclavian artery (LSA) has emerged as a crucial component in establishing a sufficient proximal landing zone. However, the technical difficulty of these procedures raises the possibility of endoleaks and neurological consequences. Single-branched stent grafts offer good anchoring and LSA flow for these patients. This study evaluates the feasibility of utilizing novel single-branched stent grafts in the treatment of distal aortic arch disease, identifying good results in the short and medium term. From September 2019 to March 2023, TEVAR and revascularized LSA were performed on ten patients at the Ospedale del Cuore—FTGM in Massa, Italy, using Castor single-branched thoracic aortic stent grafts (Microport Medical, Shanghai, China). The authors’ first findings demonstrated that, after an average follow-up of one year, the Castor branching aortic stent graft system was safe and achieving an appropriate proximal landing zone and maintaining sufficient LSA perfusion was possible. With regard to the endovascular treatment of distal aortic arch diseases, this product offers a compelling substitute for surgery. For the purpose of assessing the long-term effectiveness of this approach, the follow-up period should be extended.

1 January 2015
Verified
Journal Article
Open access
PDF file
MMMichele Murzi
Michele Murzi
MGMattia Glauber
Mattia Glauber
Central versus femoral cannulation during minimally invasive aortic valve replacement